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Abstract
Background: Approximately 40–60 % of patients remain sufferers of sequela of obstructive, restrictive or mixed
patterns of lung disease despite treatment for pulmonary tuberculosis (PTB). The prevalence of these abnormalities
in Tanzania remains unknown.
Methods: A descriptive cross-sectional study was carried out among 501 patients with PTB who had completed at
least 20 weeks of treatment. These underwent spirometry and their lung functions were classified as normal or
abnormal (obstructive, restrictive or mixed). Logistic regression models were used to explore factors associated with
abnormal lung functions.
Results: Abnormal lung functions were present in 371 (74 %) patients. There were 210 (42 %) patients with
obstructive, 65 (13 %) patients with restrictive and 96 (19 %) patients with mixed patterns respectively. Significant
factors associated with abnormal lung functions included recurrent PTB (Adj OR 2.8, CI 1.274 - 6.106), Human
Immunodeficiency Virus (HIV) negative status (Adj OR 1.7, CI 1.055 - 2.583), age more than 40 years (Adj OR 1.7, CI
1.080 - 2.804) and male sex (Adj OR 1.7, CI 1.123 - 2.614).
Conclusion: The prevalence of abnormal lung functions is high and it is associated with male sex, age older than
40 years, recurrent PTB and HIV negative status.
Keywords: Spirometry, TB sequlae, Obstruction, Restriction

Background
Tuberculosis (TB) is among the top infectious causes of
death worldwide [1]. Patients with treated TB may remain lifelong sufferers of disabling sequelae of the
disease which subsequently impair their quality of life
[2]. Many studies have shown that partially treated
pulmonary tuberculosis can result in airflow obstruction
[3–7]. Studies with longer follow-up have revealed that a
large percentage of patients with treated pulmonary tuberculosis show signs of permanent airflow obstruction or restrictive impairment [8–11]. Post tuberculosis pulmonary
impairment, therefore has emerged as a distinct clinical
entity [12].

With 170,000 reported TB cases in the year 2014,
Tanzania ranked the 18th among the 22 WHO high TB
burdened countries in the world [13]. The prevalence of
bacteriologically confirmed TB in Tanzania was 295 per
100,000 adults in the year 2010 [14]. Despite this high
burden of TB, there is no formal evidence of post tuberculous pulmonary abnormalities from Tanzania. Factors
associated with these complications or factors that may
predict long term residual abnormalities in such patients
has also been poorly addressed. This study was aimed at
determining the prevalence and the factors associated
with these abnormalities.

Methods
Study design and population
* Correspondence: mohd_manji@hotmail.com
1
Department of Internal Medicine, Muhimbili University of Health and Allied
Sciences (MUHAS), P.O. Box 65001, Dar es Salaam, Tanzania
Full list of author information is available at the end of the article

We conducted a health facility-based descriptive cross
sectional study between July and December 2014 in
Temeke municipality, the largest of three municipalities
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in Dar es Salaam city. Two busy TB clinics in this municipality, the Temeke municipal hospital and the Mbagala
rangi tatu health centre, were chosen. The target population was patients with pulmonary tuberculosis (PTB),
both sputum smear positive and smear negative TB regardless of their HIV status. Eligible patients were aged
18 years or older, had attended the clinic and completed
at least 20 of the 24 weeks of anti TB treatment. Prior
research has shown that peak lung function loss in patients with TB occurs within 6 months of diagnosis [8].
We enrolled patients who had completed 20 of the
24 weeks of anti TB treatment (i.e. 5 months), since
most of these subjects would have achieved a microbiological cure, and that such timing would enable identification of sequel of disease without considering active
disease. This timing was also reasonable in allowing data
collection for a maximal number of subjects given that
patients are discharged from the clinic at 6 months after
which it would be difficult to access them. Participants
were enrolled in a consecutive manner. The exclusion
criteria were participants who had preexisting asthma or
COPD, paraplegia, heart failure, stroke, extra pulmonary
tuberculosis, contraindications to spirometry (e.g. recent
surgery, myocardial infarction, vertigo, vomiting), spine
deformities (kyphosis, scoliosis), chest deformities, and
pregnancy.
A total of 501 participants were enrolled in the study
(Fig. 1). All participants gave consent for participation.
Ethical clearance for conducting the study was obtained

Fig. 1 Flow diagram for recruitment into the study
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from the Muhimbili University of Health and Allied
Sciences (MUHAS) institutional review board.
Data collection

Evaluations were incorporated into routine TB clinic
visits. A clinical record form (CRF) was used for data
collection. A thorough history and physical examination
was performed for each participant and recorded on the
CRF. The modified Medical research council dyspnea
scale was used to assess their functional status [15]. The
patients TB02 treatment card was used to obtain other
relevant information including duration on anti TB
treatment, serostatus for HIV and whether the PTB was
smear negative or positive for acid fast bacilli (AFB) at
diagnosis. This information was filled in the CRF. A
digital weighing scale (OMRON) was used to measure
body weight in kilograms (kg). Weight was measured in
erect position wearing only light clothing and without
shoes. Height was measured in centimeters using meter
rods. Waist circumference was measured using a tape
measure midway between the lower rib cage margin and
the anterior superior iliac spine. Mid upper arm circumference (MUAC) was measured with a tape measure
midway between the tip of the shoulder (the acromion)
and the tip of the elbow (olecranon process).
This was followed by spirometry by means of the ndd
EasyOne™ spirometer (manufactured by ndd Medizintechnik
(Switzerland)). The EasyOne™ spirometer complies with
the 2005 ATS/ERS spirometry standards. The spirometer
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does not need daily calibration [16–18]. It has been used
in several studies before both locally and internationally
[19–22]. Thus pre testing of the tool was not performed.
The device is portable and not affected by environmental
conditions. Precautionary measures in using the spirometer included the use of disposable mouthpiece (spirette)
per participant to avoid cross contamination. Spirometry
was performed in a vacant area with open sunlight and
face masks and gloves were used to protect the investigator/assistants.
The forced expiratory maneuvers, the within and
between maneuver evaluation for acceptability as well as
test result selection were in accordance with the ATS/
ERS guidelines [23]. Spirometry was performed in the
standing position. The forced expiratory maneuvers were
explained in local language by trained assistants (3 doctors and 1 nurse) to the participants before they underwent spirometry. Spirometry was performed without a
nose clip owing to the results of a pilot study among 25
patients prior to this research that observed that patients
were uncomfortable when nose clips were used during
spirometry. Furthermore, a nose clip is recommended,
but not a compulsory requirement for spirometry [23]
and other studies have not shown significant differences
in results among users and non-users of nose clips
[24, 25]. Disposable mouthpieces (spirettes) were discarded after individual use. Parameters measured included
forced expiratory volume in one second (FEV1) and the
forced vital capacity (FVC). The highest FEV1 and FVC
from three acceptable maneuvers were used for further
comparison and analysis. The FEV1: FVC% was then
calculated from these.
Data analysis

The lung functions were categorized into normal, obstruction, restriction and mixed patterns of lung disease
according to the algorithm from the National Lung
Health Education Program (NLHEP) [26].
The predicted values were derived from regression
equations for healthy Tanzanian adults [22]. To compare
the observed and predicted lung functions, we used the
percentage of predicted values (the ratio of observed to
predicted values times 100) for FVC (FVC %) and FEV1
(FEV1%). Severity for obstruction and restriction were
graded according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) [27] and the American
Thoracic Society/European Respiratory Society (ATS/
ERS) task force recommendations [28] respectively.
Data was analyzed using SPSS (version 15.0) statistical
software. Means ± standard deviation (SD) and proportions were calculated for continuous and categorical data
respectively. Median and interquartile range (IQR) was
used for non-normally distributed numerical data. The
Chi square test and t-test were used to determine
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associations between variables. If more than 20 % of the
cells had an expected frequency of <5, Fischer’s exact
test was used instead.
Logistic regression was done to determine predictors
of abnormal lung function. The dependent variable was
lung function which was reported as normal or abnormal.
The independent variables that were run in multivariate
models were those that had a p value of < 0.2 in univariate
analysis. These included age, sex, level of education, Modified Medical Research Council Dyspnea Score (MMRC
Score), smoking status, sputum smear status at diagnosis
(positive or negative), TB episode number (first episode or
recurrent), duration from symptoms to diagnosis of TB,
HIV serostatus (positive or negative) and CD4 counts.
Statistically significance was achieved when p < 0.05.

Results
Study population

There were a total of 501 participants in the study
(Fig. 1). Males constituted 60.5 % (303/501) of the study
participants. More than 60 % (326/501) of participants
were aged 40 years or younger. Majority were married
or cohabiting (52.5 %) (263/501), had attained primary
level education (65.9 %) (330/501) and were domestic
workers (34.1 %) (171/501). Approximately 29.3 % (147/
501) were ever smokers with a median of 2.5 pack years.
With respect to their clinical characteristics, approximately 54.3 % (272/501) had smear positive pulmonary
TB and 90.1 % (245/272) of these had converted to
smear negative at 2 months of treatment. Majority
(85 %) (426/501) of the patients had presented with a
first episode of TB. The median time from first symptom
presentation to TB diagnosis was 30 days. Approximately 30 % (152/501) of the population was HIV coinfected. Approximately 46 % (70/152) of the patients
had CD4+ cell count <200cells/μL. Majority (81 %)
(407/501) had good functional scores (1 to 2) for dyspnea as reported by the MMRC score (Table 1). The
mean FEV1, FVC and FEV1: FVC% were 1.83 ± 0.75,
2.95 ± 1.11 and 63.02 ± 17.99 respectively.
Prevalence and severity of abnormal lung functions

The overall prevalence of lung function abnormalities
was 74 % (371/501). Majority was due to obstruction
(42 %) (210/501) followed by mixed (19 %) (96/501) and
restrictive (13 %) (65/501) abnormalities. Approximately
73 % (48/65) of patients with restrictive dysfunction has
mild to moderate severity. Approximately 79 % (166/
210) of patients with obstructive dysfunction had mild
to moderate severity (Fig. 2).
Factors associated with abnormal lung functions

Patients who were aged 40 years or younger were less
likely to present with abnormal lung functions (69.9 %)
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Table 1 Sociodemographic and clinical characteristics of
participants

Table 1 Sociodemographic and clinical characteristics of
participants (Continued)

Characteristics (N = 501)

Duration to TB diagnosis (months)

Frequency Percent
(%)

Age Groups (years)
18–30

166

33.1

31–40

160

31.9

41–50

96

19.2

51–60

42

8.4

>60

37

7.4

Sex
Male

303

60.5

Female

198

39.5

275

54.9

>1 Month

226

45.1

Positive

152

30.3

Negative

349

69.7

<200

70

46.2

200–350

50

33.0

>350

32

20.9

HIV Status

CD4 count (n = 152)

MMRC Score Modified Medical Research Council Dyspnea Score, BMI Body
Mass Index, IQR Interquartile range

Marital Status
Single

169

33.7

Married/Cohabiting

263

52.5

Divorced/Widowed

69

13.8

Education
No Formal

62

12.4

Primary

330

65.9

Secondary

84

16.8

Post-Secondary

25

5.0

19

3.8

Occupation
Agriculture

≤1 Month

Domestic

171

34.1

Industrial

64

12.8

Office

119

23.8

Other

128

25.5

1–2

407

81.2

3–5

94

18.8

MMRC score

Cigarette smoking
Never smokers

354

70.7

Ever Smokers

147

29.3

Smoking Pack Years (Median (IQR))

2.5 (5.3)

Smear for Acid Fast Bacilli
Positive

272

54.3

Negative

229

45.7

Smear Negative at 2 Months

245

90.1

Smear Positive at 2 Months

27

9.9

First

426

85.0

Recurrent

75

15.0

Time to Negative Sputum Conversion
(months)(n=272)

TB Episode

compared to those older than 40 years (81.7 %), p = 0.004.
Abnormal lung function was more prevalent among males
(78.9 %) than among females (66.7 %) (p = 0.002). However more males developed restrictive (p = 0.034) and
mixed (p < 0.001) abnormalities while more females developed obstruction (p < 0.001) (Table 2). As far as clinical
characteristics are concerned, higher MMRC scores were
significantly associated with any abnormality (84 % for
scores 3–5 vs 71.7 % for score 1–2) (p = 0.013). A similar
finding was seen for mixed abnormalities (p = 0.009).
However lower scores were significantly more associated
with obstruction (p = 0.04). Patients who had more than 5
pack years of smoking had significantly higher obstructive
abnormalities than those who had smoked for less than 5
pack years (73.3 % vs. 41.9 %) (p =0.005). Patients with recurrent TB were also more likely to have abnormal lung
functions compared to those with a first episode of TB
(89.3 % vs 71.4 %) (p = 0.001). Also HIV negative patients
constituted significantly greater percentage of individuals
with abnormal lung functions (77.1 %) compared to HIV
infected patients (67.1 %) (p = 0.019). This relationship
was also true for mixed lung disease (p = 0.012). However
obstructive dysfunction was more common in HIV infected (66.7 %) than in HIV negative patients (52.4 %)
(p = 0.014) (Table 3).
In multivariate analysis significant predictors for any
abnormality were age > 40 years (Adj OR 1.740, CI
1.080 - 2.804), male sex (Adj OR 1.713, CI 1.123 - 2.614),
TB recurence (Adj OR 2.789, CI 1.274 - 6.106) and HIV
negative status (Adj OR 1.651, CI 1.055 - 2.583) (Table 4).

Discussion
The prevalence of abnormal lung functions of any type
in this study was 74 % and the prevalence of individual
patterns of impairment was 42, 13 and 19 % for obstructive, restrictive and mixed patterns of lung disease
respectively. These findings indicate a huge burden of
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Fig. 2 Prevalence and severity of abnormal lung functions. Pie charts showing the prevalence of the different types of lung function abnormalities
(large pie chart, N = 501). The smaller pie charts show the severity of patients who had restrictive (small upper, n = 65) and obstructive abnormalities
(small lower, n = 210)

Table 2 Sociodemographic factors associated with abnormal lung functions
Characteristics

Total

Any Abnormality

P

Obstructive

P

Restrictive

P

Mixed

P

≤40 years

326

228

69.9 %

0.004*

121

53.1 %

0.132*

46

20.2 %

0.163*

61

26.8 %

0.715*

>40 years

175

143

81.7 %

88

61.5 %

20

14.0 %

35

24.5 %

Males

303

239

78.9 %

112

46.9 %

50

20.9 %

77

32.2 %

Female

198

132

66.7 %

97

73.5 %

16

12.1 %

19

14.4 %

Age groups (number, %)

Sex (number, %)
0.003*

<0.001*

0.034*

<0.001*

Marital Status (number, %)
Single

169

120

71.0 %

64

53.3 %

23

19.2 %

33

27.5 %

Married/Cohabiting

263

201

76.4 %

0.432

115

57.2 %

0.679

36

17.9 %

0.723

50

24.9 %

Divorced/W idowed

69

50

72.5 %

30

60.0 %

7

14.0 %

13

26.0 %

No Formal Education

62

47

75.8 %

29

61.7 %

7

14.9 %

11

23.4 %

Primary Education

330

249

75.5 %

148

59.4 %

45

18.1 %

56

22.5 %

0.874

Education (number, %)
0.080

0.063

0.912

Secondary Education

84

62

73.8 %

26

41.9 %

11

17.7 %

25

40.3 %

Post-Secondary Education

25

13

52.0 %

6

46.2 %

3

23.1 %

4

30.8 %

19

18

94.7 %

11

61.1 %

1

5.6 %

6

33.3 %

0.036

Occupation (number, %)
Agriculture

0.05

0.005

0.236

Domestic

171

119

69.6 %

81

68.1 %

19

16.0 %

19

16.0 %

Industrial

64

44

68.8 %

16

36.4 %

10

22.7 %

18

40.9 %

Office

119

96

80.7 %

53

55.2 %

14

14.6 %

29

30.2 %

Other

128

94

73.4 %

48

51.1 %

22

23.4 %

24

25.5 %

* fishers exact

0.013
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Table 3 Clinical factors associated with abnormal lung functions
Characteristics

Total

Any Abnormality

P

Obstructive

P

Restrictive

P

1–2

407

292

71.7 %

0.013*

173

59.2 %

0.04*

53

18.2 %

0.868*

3–5

94

79

84 %

36

45.6 %

13

16.5 %

Mixed

P

66

22.6 %

0.00

30

38.0 %

9*

MMRC score (number, %)

Cigarette smoking (number, %)
Never smokers

354

255

72.0 %

Ever Smokers

147

116

78.9 %

0.118*

151

59.2 %

58

50.0 %

36

41.9 %

22

73.3 %

0.114*

49

19.2 %

17

14.7 %

16

18.6 %

1

3.3 %

0.309*

55

21.6 %

0.00

41

35.3 %

7*

34

39.5 %

0.12

7

23.3 %

6*

Smoking Pack Years (number, %) (n=147)
≤5

107

86

80.4 %

>5

40

30

75.0 %

0.5*

0.005*

0.068*

Smear for Acid Fast Bacilli (number, %)
Smear Positive

272

198

72.8 %

Smear Negative

229

173

75.5 %

0.54*

110

55.6 %

99

57.2 %

11

57.9 %

99

55.3 %

0.754*

31

15.7 %

35

20.2 %

3

15.8 %

28

15.6 %

0.278*

57

28.8 %

0.19

39

22.5 %

2*

26.3 %

1.0*

Time to Negative Sputum Conversion (number, %)
Smear Positive at 2 Months

27

19

70.4 %

Smear Negative at 2 Months

245

179

73.1 %

0.82*

1.0*

1.0*

29.1 %

TB Episode Number (number, %)
First

426

304

71.4 %

Recurrent

75

67

89.3 %

0.001*

171

56.3 %

38

56.7 %

117

56.5 %

92

56.1 %

1.0*

59

19.4 %

7

10.4 %

40

19.3 %

26

15.9 %

0.111*

74

24.3 %

0.16

22

32.8 %

6*

50

24.2 %

0.40

46

28.0 %

6*

Duration to TB diagnosis (mo) (number, %)
≤1 Month

275

207

75.3

>1 Month

226

164

72.6

HIV Positive

152

102

67.1 %

HIV Negative

349

269

77.1 %

0.539*

1.0*

0.414*

HIV Status (number, %)

CD4 count (Median (IQR))

0.026*

68

66.7 %

141

52.4 %

202.50 (210)

0.014*

17

16.7 %

49

18.2 %

192.5 (225)

0.764*

200 (156)

17

16.7 %

0.01

79

29.4 %

2*

260(167)

* fishers exact, MMRC score Modified Medical Research Council Dyspnea score, BMI Body Mass Index, IQR Interquartile range

Table 4 Logistic regression analysis of sociodemographic and clinical parameters
Characteristic (n = 501)

Comparison

OR

95 % CI

P

Adj OR

95 % CI

P

Age >40 years

≤40 years

1.921

1.224–3.014

0.005

1.740

1.080–2.804

0.023

Male

Female

1.867

1.24 -2.797

0.002

1.713

1.123–2.614

0.013

Any Formal Education

No Formal

0.899

0.944–8.087

0.736

-

-

-

MMRC score 3–5

MMRC ≤2

2.074

1.147 -3.752

0.016

1.786

0.962–3.316

0.066

Ever Smoker

Never smoker

1.453

0.918–2.300

0.111

-

-

-

Smear Positive TB

Smear Negative

0.866

0.579–1.296

0.484

-

-

-

Smear Positive at 2 months

Smear negative at 2 months

0.876

.366–2.096

0.766

-

-

-

TB recurrence (Any recurrence)

1st episode

3.361

1.568–7.206

0.002

2.789

1.274–6.106

0.010

Duration to Diagnosis >1 month

≤1 months

0.869

0.582–1.297

0.492

-

-

-

HIV Negative

HIV Positive

1.648

1.082–2.510

0.020

1.651

1.055–2.583

0.028

CD4 count >350

<350

0.362

0.124–1.059

0.064

-

-

-

MMRC Score Modified Medical Research Council Dyspnea Score, Adj Adjusted
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post treatment pulmonary function abnormalities in
patients with pulmonary tuberculosis. It was also found
that majority of patients with obstructive and restrictive
abnormalities had mild to moderate severity. The findings of the present study are similar to those done elsewhere. For instance, in a study by Pasipanodya et al.
(2007) in the USA, the prevalence of abnormal lung
function of any type was 59 % and the prevalence of individual subtypes of impairment for obstructive, restrictive
and mixed were 15, 31 and 13 % respectively [29]. While
the prevalence of pulmonary impairment was higher in
our study, it suffices to note that pulmonary functions are
abnormal in the majority of patients upon completion of
chemotherapy. This has been a consistent finding in studies done in other parts of the world [6, 9, 30].
A striking difference can be observed in the proportion of obstructive lung disease between the Pasipanodya
study and the present study. The present study revealed
a markedly higher proportion of patients who had obstructive lung disease (42 % vs 15 %). In some studies
pulmonary infections (like childhood pneumonias,
pneumocystis jirovecii, pertussis and measles) contribute
up to a third of cases of obstructive airway disease
[31–36]. Childhood pneumonias and measles are
common in Tanzania. Other studies have found that
the odds of developing obstructive disease may be
even higher with TB than with smoking [19, 37, 38].
Poor socioeconomic status [39] and low birth weights
[40] have also been linked with the development of
obstructive impairments both of which are applicable
to the Tanzanian setup. For example, 9.7 % of the Tanzanian
population are below the food and poverty line [41] and
13 % of Tanzanian newborns are low birth weight [42].
Therefore, a predominance of obstructive sequelae after TB
may not be so surprising in this part of the world.
We have shown that patients who presented with recurrent tuberculosis had a 2.8 fold higher likelihood of
developing abnormal lung functions at the end of treatment than those with a first episode of TB. Considering
that Tanzania is among the high burden countries, the
burden of recurrent TB is also high. Studies in other
parts of the world have also shown recurrent tuberculosis to be associated with adverse spirometric outcomes.
In a population wide Korean study, Lee and colleagues
showed that previous TB predicted almost 3 fold higher
chance of developing obstructive lung disease [43]. Another
South African study of approximately 27,000 miners
showed incremental rise in lung function abnormalities
with the number of TB episodes (18, 27 and 35 % among
first, second and third time sufferers of TB respectively) [8].
In the present study, it was found that HIV negative
individuals had a 1.7 fold more likelihood of presenting
with any form of lung impairment than were HIV infected patients. These findings can be explained by the
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fact that the mechanisms by which tuberculosis damages
the lung depend extensively on cell mediated immune
processes [44]. Many typical tuberculous changes may
not be found in individuals who are HIV infected due to
defects in their cell mediated immunity. These have been
shown in studies comparing radiographic presentations
of TB among HIV positive and negative individuals [45].
For example, HIV infected patients may not have typical
upper lobe involvement or form typical cavities which
confer significant structural alteration to the lung
morphology [45]. As a result, it is likely that HIV positive patients end up with less spirometric abnormalities
for lack of gross functional alteration due to relatively
preserved lung parenchyma unlike their HIV negative
counterparts.
The findings of this study warrant an active search
among TB patients for these abnormalities. According to
these results, practitioners in TB clinics can predict
patients who may be at a higher risk for these impairments. Patients with recurrent tuberculosis, patients
who are HIV negative, male patients and patients older
than 40 years run the highest risk of these abnormalities.
The tools to detect such abnormalities are fairly simple,
rapid and not overly costly and there should not be a
reason to miss this population who may require assistance beyond standard anti tuberculous therapy.
One may argue that these results actually make a case
for an even more intensified and rapid detection of TB
patients such that earlier treatment may offset the development of these sequelae. While this concept looks
plausible in theory, the findings of the present study suggest otherwise. In a subgroup analysis of duration of
symptoms to TB diagnosis and lung function, there was
no significant difference among patients who were diagnosed and started treatment within 1 month against
those who were diagnosed and started treatment later
(Table 3). This relationship was also non-significant for
obstructive, restrictive and mixed disease suggesting that
simply having tuberculosis imparts a risk irrespective of
how soon treatment is started.
The prevalence of these abnormalities among patients
completing anti TB is alarmingly high. The morbidity
and impairment in quality of life conferred by these sequelae is likely to be similarly high. While such data on
long term morbidity is missing in Tanzania, literature
from other parts of the world suggests that these sequelae confer a significant impact on everyday functioning
and quality of life [2, 46–48]. In fact, some studies suggest greater morbidities from the sequelae rather than
from the disease itself [2, 48]. These non-communicable
post tuberculous sequelae bring to light the often overlooked processes by which TB impacts quality of life.
Tuberculosis therefore imposes an infectious and noninfectious burden to the healthcare infrastructure. While
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the infectious and microbiologic domain has received
much attention in TB treatment, a lot is still left to be
desired in the non-infectious sequela.

Conclusions
The magnitude of residual lung function abnormalities
among patient with tuberculosis is high despite successful
administration of anti TB medications. Important factors
associated with abnormal lung functions include recurrent
TB, HIV negative status, age more than 40 years and male
sex. The findings of this study warrant an active search of
these impairments among TB patients. Studies that look
at the quality of life and socioeconomic impact of residual
lung function abnormalities, screening strategies and
treatment need to be conducted to supplement the findings of this study.
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